TCTR20220504002尚未招募1 期
Bioequivalence Study of 25 mg Agomelatine FCT in Healthy Thai Volunteers
nison Laboratories Co., Ltd.0 个研究点目标入组 46 人开始时间: 2022年5月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Healthy Thai male or female volunteers aged between 18 and 55 years.
- •2. The Body Mass Index (BMI) ranges from 18.5 to 25 kg/m2.
- •3. Determined healthy by medical history, physical examination and vital signs
- •4. The results of the clinical laboratory tests are within clinically acceptance limits i.e., blood urea nitrogen (BUN), serum creatinine, AST, ALT, total bilirubin, alkaline phosphatase, GGT, blood potassium, sodium, calcium, chloride, fasting blood sugar and hematology examinations including differential blood counts and HBsAg test. Some of the clinical laboratory values that out of the normal range will be carefully considered by clinical investigator.
- •5. Negative pregnancy test for female volunteers and effective contraceptive must be used at least 14 days prior to the study initiation and not breast-feeding women.
- •6. Male volunteers who are surgically sterile or agree to use an effective contraception throughout the study.
- •7. Willing to participate in the study and signed the informed consent form.
排除标准
- •1. History or evidence of allergy or hypersensitivity to agomelatine or any of the excipients of this product or any related drugs.
- •2. History or evidence of allergy or hypersensitivity to heparin.
- •3. History or evidence of hypertension (systolic BP 140 mmHg, diastolic BP 90 mmHg) or hypotension (systolic BP <90 mmHg, diastolic BP <60 mmHg).
- •4. History or evidence of gastrointestinal, hepatic, renal, cardiovascular, hemato-logical disease or allergic disease or bronchial asthma or any disease that may affect the bioavailability of drug.
- •5. Evidence of more than one abnormal ECG which is considered as clinically significant.
- •6. History of chronic or debilitating diseases.
- •7. Positive HBsAg tests.
- •8. History of alcoholism or drug abuse.
- •9. Positive urine drug abuse tests (Benzodiazepines, Methamphetamine and Opi-ates).
- •10. History of regular alcohol consumption (more than 1 time a week) or alcohol consumption within 7 days prior to the study drug administration and until the completion of the study.
- •11. History of smoking more than 10 cigarettes/day, or moderate smokers (less than 10 cigarettes/day) and could not quit at least 7 days prior to the study drug administration and until the completion of the study.
- •12. Tea/coffee or caffeine- or xanthine-containing beverage consumption within 7 days prior to the study drug administration and until the completion of the study.
- •13. Grapefruit juice or grapefruit-containing products consumption within 7 days prior to the study drug administration and until the completion of the study.
- •14. Use of any prescription drugs or over-the-counter (OTC) drugs or herbal medi-cines within 30 days or vitamins or food supplements within 14 days prior to the study drug administration or use hormonal methods of contraception with-in 28 days (discontinuation for at least 6 months is required for Depo-Provera use) prior to receiving the first dose of the study medication.
- •15. Blood donation or blood loss over 350 mL within 90 days before the study.
- •16. Participation in any clinical studies within 90 days before the study.
研究者
相似试验
已完成
不适用
Bioequivalence study of Agomelatine 25 mg in healthy volunteer under fasting conditioBioequivalence study of agomelatine 25 mgTCTR20200903006nison Laboratories Co., Ltd.36
进行中（未招募）
不适用
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-blind, placebo-controlled, parallel groups, international study. - NDMedDRA version: 12.1Level: LLTClassification code 10029898Term: Obsessive-compulsive disorderObsessive-compulsive disorderEUCTR2009-016713-20-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER80
尚未招募
2 期
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder.A randomised, double-blind, placebo-controlled, parallel groups, international study.psychiatrische en obsessieve en compulsieve stoornissenObsessive Compulsive DisorderNL-OMON34855Servier R&D Benelux15
进行中（未招募）
1 期
Efficacy of Agomelatine in Patients with Obsessive-compulsive DisorderMedDRA version: 14.1 Level: PT Classification code 10029898 Term: Obsessive-compulsive disorder System Organ Class: 10037175 - Psychiatric disordersObsessive-compulsive disorderEUCTR2009-016713-20-GBInstitut de recherches Internationales Servier80
进行中（未招募）
不适用
Efficacy of agomelatine in Patients with Obsessive-Compulsive DisorderMedDRA version: 14.1Level: PTClassification code 10029898Term: Obsessive-compulsive disorderSystem Organ Class: 10037175 - Psychiatric disordersObsessive-compulsive disorderEUCTR2009-016713-20-SEInstitut de recherches Internationales Servier80